Fortress Biotech (FBIO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
Meeting called to order by the Executive Chairman, President, and CEO, with directors introduced and present via remote communication.
Independent auditors, legal counsel, CFO (serving as Secretary), and Inspector of Elections were introduced.
Agenda included accepting motions, collecting votes, and reporting results.
Shareholder proposals
Two motions presented: election of directors to serve until the 2027 annual meeting and ratification of KPMG as independent auditors for 2026.
Overview of voting outcomes
Quorum confirmed with a majority of shares represented as of the record date.
All director nominees were approved.
Ratification of KPMG as independent auditors for 2026 was approved.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fortress Biotech
- Two FDA approvals and a major acquisition highlight Fortress Biotech's transformative 2024.FBIO
Q4 202411 Jun 2026 - Three FDA approvals, strong revenue, and a robust late-stage pipeline drive near-term growth.FBIO
Corporate presentation11 Jun 2026 - Q1 2026 net income jumped to $108.4M on a $205M PRV sale and 21–22% revenue growth.FBIO
Q1 202626 May 2026 - Scalable, royalty-driven model and recent monetizations fuel growth and strengthen financial position.FBIO
A.G.P.'s Annual Virtual Healthcare Conference20 May 2026 - Shareholders will vote virtually on director elections, auditor ratification, and equity-based executive pay.FBIO
Proxy filing29 Apr 2026 - Virtual vote set for June 2026 on director elections and auditor ratification.FBIO
Proxy filing29 Apr 2026 - Three FDA approvals, major asset monetizations, and a robust pipeline drive near-term growth.FBIO
Corporate presentation22 Apr 2026 - Revenue rose 10% to $63.3M, with improved margins and major asset sales boosting liquidity.FBIO
Q4 202531 Mar 2026 - ZYCUBO approval and early treatment boost survival in Menkes disease; gene therapy advances.FBIO
Corporate presentation26 Mar 2026